<DOC>
	<DOCNO>NCT03003260</DOCNO>
	<brief_summary>Rationale : IBS common functional gastrointestinal disorder prevalence worldwide range 9-23 % . Complaints include abdominal discomfort pain alter bowel habit . Although condition life-threatening , strongly impair quality life cure IBS . It assume IBS symptom related combination alter gut motility secretion , visceral hypersensitivity . However , primary cause still remain largely unknown . The endocannabinoid system , together functionally related receptor among biological target consider promising treatment . Modulation CB1 , CB2 relate receptor enzymes endocannabinoid system broad sense ( endo ) cannabinoids ( ) structurally relate lipid mediator influence motility , secretion decrease hypersensitivity gut . Among plant-derived cannabinoids call 'phytocannabinoids ' , cannabidiol ( CBD ) special interest show therapeutic potential preclinical study grow number case-reports . CBD non-specific phytocannabinoid display broad weak receptor interaction profile . In contrast well-known THC Cannabis sativa , CBD psychoactive often also present Cannabis variety use psychoactive property industrial ( fibre ) food property ( oil , flour seed ) instead . Based preclinical study vitro data hypothesize CBD might able relieve symptom IBS , include pain patient IBS . The chew gum take 'on demand ' may additional perceive positive effect . Objective : To investigate whether use CBD-containing preparation form CanChew® chew gum contribute reduction IBS symptom improvement perceive wellbeing patient IBS . Study design : A randomized , double-blind , cross-over trial 8 week total . Study population : Adults , age 18-65 , diagnose accord ROME III criterion Irritable Bowel Syndrome . Intervention ( applicable ) : Patients , cross-over study , receive maximum 6 chew gum per day , either contain 50 mg cannabidiol per chew gum case CanChew chew gum , placebo chew gum . This first intervention period last 3 week . Next , participant undergo one week wash-out switch intervention either placebo CanChew chew gum another 3 week . Main study parameters/endpoints : The main study parameter change pain reduction perception experience measure patient use VAS-scales take chew gum , record diary . Next patient ask provide one VAS score complete week . Furthermore , adequate relief measure every day . At end week patient also ask ( diary ) whether noticed change stool frequency ( ) experience side-effects . For disease-related quality life IBS-QOL use . This questionnaire fill week 1 , 4 , 5 , 8 .</brief_summary>
	<brief_title>The Effect CanChew® Cannabidiol ( CBD ) Containing Chewing Gum Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Male Female , use contraceptive pill Adults , age 1865 IBS , diagnose accord Rome III criteria More 3 moment pain vasscore 4 high per week Signed informed consent Use SSRIs , tramadol tramagetic Have history intestinal surgery might interfere outcome study Female patient : currently pregnant breastfeed hope become pregnant study , judge person self . Female use contraceptive pill . Are employee student department Human Nutrition Wageningen UR , employee MDL department hospital Gelderse Vallei Participate another research study Alcohol use ( male 14 serving week , female 7 serving week ) Cannabis use 3 month end study allow . Hypersensitivity one ingredients chew gum Drug use ( CYP2C19 CYP3A4 ) metabolise ; medication evaluate principal medical investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>